Ticker Details
MannKind Corporation MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.
IPO Date:	July 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$790.52M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 3.01%
Avg Daily Range (30 D):	$0.08 | 2.68%
Avg Daily Range (90 D):	$0.12 | 2.61%

Institutional Daily Volume
Avg Daily Volume:	2.1M
Avg Daily Volume (30 D):	5.81M
Avg Daily Volume (90 D):	4.1M

Trade Size
Avg Trade Size (Sh.):	225
Avg Trade Size (Sh.) (30 D):	270
Avg Trade Size (Sh.) (90 D):	202

Institutional Trades
Total Institutional Trades:	3,911
Avg Institutional Trade:	$1.58M
Avg Institutional Trade (30 D):	$2.25M
Avg Institutional Trade (90 D):	$2.52M
Avg Institutional Trade Volume:	.25M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$2.67M
Avg Closing Trade (90 D):	$3.18M
Avg Closing Volume:	380.48K

News

Mar 18, 2026 @ 2:00 PM A Key "Master" Protein That Declines by Half After... Source: Equity-Insider.Com

Feb 26, 2026 @ 11:19 PM Why MannKind Stock Tumbled on Thursday Source: Eric Volkman

Feb 19, 2026 @ 2:00 PM MannKind to Participate in the Oppenheimer 36th An... Source: Na

Jan 29, 2026 @ 6:31 PM Longevity Biotech Stocks Surge as $27 Trillion Hea... Source: Prnewswire

Jan 23, 2026 @ 5:56 PM Breaking Barriers: How 2026’s Top Clinical ... Source: Equity Insider

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$.02	$-.05	$.02
Diluted EPS	$.02	$-.05	$.02
Revenue	$348.97M	$111.96M	$348.97M
Gross Profit	$322.17M	$98.03M	$322.17M
Net Income / Loss	$5.86M	$-15.95M	$5.86M
Operating Income / Loss	$38.8M	$-7.69M	$38.8M
Cost of Revenue	$26.8M	$13.93M	$26.8M
Net Cash Flow	$28.55M	$-52.51M	$28.55M
PE Ratio	128.50

Splits
Mar 03, 2017	1:5